Abstract 1377P
Background
The most common solid systemic malignancies that metastasize to the leptomeninges are lung cancer. Generally, patients develop leptomeningeal metastasis (LM) subsequent to brain parenchymal metastases (BM). However, its predictors remain unknown. Hence, this study was conducted to explore the predictors of LM in brain metastatic NSCLC patients.
Methods
The final analysis included 112 pathologically definite NSCLC patients with BMs treated in our center between July 1, 2014, and December 30, 2020. Of 112, one-half had LM. Three radiologists analyzed radiologic images independently. Anatomic proximity of BMs to the CSF space (dural-based metastases, periventricular or major CSF cisterns such as basal cisterns and cisterna magna) was measured and stratified into CSF space invading/bordering and detached lesions. The endpoint was the occurrence of LM or death, whichever occurred first. Uni- and multi-variable logistic regressions were performed to identify potential predictors for LM.
Results
Of 112, 48 (42.8%) were males, and 64 (57.2%) were females. Most patients (90.2%) had adenocarcinoma histology. The median follow-up time was 10.1 months (IQR, 4.2-18.4 months) following BM diagnosis. Univariate logistic regression analysis demonstrated that histology (OR 0.084, 95%CI 0.004-0.461, P=0.020), EGFR/ALK/ROS1 mutation (OR 3.868, 95%CI 1.583-10.079, P=0.003), CSF space invading/bordering lesion (OR 10.278, 95%CI 4.203-27.375, P=0.000), extracranial metastasis control (OR 2.7, 95%CI 1.191-6.309, P=0.019), upfront stereotactic radiosurgery (SRS) (OR 0.024, 95%CI 0.001-0.12, P=0.000), and target therapy (OR 4.476, 95%CI 1.877-11.464, P=0.001) were the potential predictor. CSF space invading/bordering lesion (OR 7.443, 95%CI 2.099-32.853, P=0.003) and upfront SRS (OR 0.035, 95%CI 0.002-0.212, P=0.003) remained statistically significant in the multivariate logistic regression analysis.
Conclusions
CSF space invading/bordering BMs may increase the risk of LM development in brain metastatic NSCLC patients, while upfront SRS targeting BM potentially decreases the risk. A prospective study is warranted to affirm.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1773P - Genomic and transcriptomic analysis of chondrosarcomas to explore new potential treatment options
Presenter: Konstantin Zirov
Session: Poster session 06
1774P - Immunological-molecular profiling of chondrosarcoma (ChS)
Presenter: Piotr Rutkowski
Session: Poster session 06
1775P - Peripheral blood (PB) T cell phenotype and tumor microenvironment (TME) subtype are independently associated with immune checkpoint blockade (ICB) outcomes in sarcomas
Presenter: Evan Rosenbaum
Session: Poster session 06
1776P - Targeting B7H3 biomimetic nanoparticles for strengthening osteosarcoma photodynamic therapy through aggravating DNA damage
Presenter: Tianqi Luo
Session: Poster session 06
1777P - Molecular profiling from next-generation sequencing (NGS) reveals new potential therapeutic targets in patients with pediatric-type sarcomas
Presenter: Anthony Conley
Session: Poster session 06
1778P - Clear cell sarcomas (CCS) express Gp100: A novel immune target for a bispecific T cell engager
Presenter: Elise Nassif Haddad
Session: Poster session 06
1779P - Deep learning tertiary lymphoid structures detection on HES/H&E slides and association to survival outcome in sarcoma
Presenter: Lucile Vanhersecke
Session: Poster session 06
1780P - Homologous recombination pathway in sarcomas: A novel opportunity of therapy?
Presenter: María del Carmen Garijo Martínez
Session: Poster session 06